About this calculator:
The International Prognostic Index (IPI) and the age-adjusted IPI were developed for patients with aggressive Non-Hodgkin’s Lymphoma (NHL) treated with anthracycline-based chemotherapy.1 Both prognostic indices (PI) have since then been validated for immunocompetent patients with newly diagnosed NHL, treated with rituximab plus doxorubicin-containing chemotherapy.2 The scores are able to categorize patients based on baseline patient- and lymphoma-characteristics into three risk groups: low risk, intermediate risk and high risk.
Outcomes for patients with HIV who are newly diagnosed with aggressive NHL have substantially improved over time, but HIV-positive patients have other competing risks for death compared to immunocompetent patients. The ARL-IPI has been developed for patients treated in the era of combination antiretroviral therapy (cART) who are being treated with rituximab-containing chemoimmunotherapy and has been shown to more accurately predict survival than the aaIPI or IPI.3
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med 329:987-994, 1993
- Ziepert M, Hasenclever D, Kuhnt E, et al: Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology 28:2373-2380, 2010
- Barta SK, Xue X, Wang D, et al: ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era. ASH Annual Meeting Abstracts 120:1564, 2012